Details For Selected Brain Tumor Treatment

Sponsored By

Please Click On The Above Banner For More Details

Back to New Treatments List


		Treatment Name:		Phase III, randomised, parallel Group, multi-centre study in recurrent glioblastoma patients to compare the efficacy of cediranib monotherapy and the combination of cediranib with lomustine to the efficacy of lomustine alone

		Phase:		Phase 3

		Treatment ID#:		1900 2007-0671

		Age Group:		Adults Only

		Min Karnofsky Score:		70: Cares for self, unable to perform normal activity or to do active work

		Conditions:		Prior Surgery is Allowed Prior Radiation is Allowed Prior Chemotherapy is Sometimes Allowed recurrent glioblastoma

		Last Updated:		04/03/2009

		Tumor Types:		Glioblastoma Multiforme


		Comments:		Cediranib is a small molecule tyrosine kinase inhibitor of VEGF signaling. Study may include tumor tissue biomarker analysis and pharmacogenetic study of blood samples, as well as quality of life studies. Only one prior systemic chemotherapy regimen permitted, and that regimen must have included temozolomide. Prior Gliadel wafers are permitted (considered local, not systemic therapy)

		Treatment Type:		Chemotherapy Immunological, Biological or Targeted Therapy

		Contact:		Jan Esenwein Program Coordinator, Brain Tumor Program MD Anderson Cancer Center 1515 Holcombe Blvd Houston, TX 77030- USA Phone: (713)745-2264 Fax: (713)794-4999 E-mail: jesenwei@mdanderson.org Website: www.mdanderson.org/diseases/braincancer/

Last updated refers to the date when our listing for each treatment was last updated.
ID is a combination of our internal ID and the official ID for the trial, if any.
Min Karnofsky is a general guide to how well you have to function to use this treatment

Translate this pageMicrosoftÂ® Translator

Copyright (c) 1993 - 2009 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740

Website Design By